Zenas BioPharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Zenas BioPharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 88% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-9.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 50% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-154.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 88% of Healthcare companies in United States.
Cash Cushion Ratio
+19%Cash, after subtracting all debt, equals 19% of its market value (net cash).
Higher than 61% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Zenas BioPharma, Inc. made a loss over the last year. Zenas BioPharma, Inc. owes $0.65 for every $1 it owns. Zenas BioPharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossZenas BioPharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
7.45The share price is 7.45 times Zenas BioPharma, Inc.'s book value per share, higher than 81% of Healthcare companies in United States.
Market cap
$1.8 BThe total market value of all of Zenas BioPharma, Inc.'s shares at today's price (share price × number of shares), larger than 73% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$247 MWhat Zenas BioPharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.79Net worth divided by the number of shares. The share price of $28.23 is 7.4 times this, which is the P/B above.
Return on equity (ROE)
-199.0%Zenas BioPharma, Inc. lost 199.0% of its shareholders' money over the last year, lower than 84% of Healthcare companies in United States.
Owes vs Owns
0.65×Zenas BioPharma, Inc. owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Dividend yield
NoneZenas BioPharma, Inc. does not currently pay a dividend.
Revenue growth
+100%Revenue rose 100% in the year to Dec 2025.
Profit growth
LossZenas BioPharma, Inc. made a loss in each of the last two years.
Profit margin
-3777.4%Zenas BioPharma, Inc. lost $3777 for every $100 of revenue.
Interest cover
Not coveredZenas BioPharma, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashZenas BioPharma, Inc. held $342 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Zenas BioPharma, Inc.: $1.8 B ÷ $247 M (30 Jun 2026) = 7.4.
What is Zenas BioPharma, Inc.'s return on equity?
Zenas BioPharma, Inc. lost 199.0% of its shareholders' money over the last year, lower than 84% of Healthcare companies in United States.
How much does Zenas BioPharma, Inc. owe compared with what it owns?
Zenas BioPharma, Inc. owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Does Zenas BioPharma, Inc. pay a dividend?
No. Zenas BioPharma, Inc. does not currently pay a dividend.
Is Zenas BioPharma, Inc.'s revenue growing?
Revenue rose 100% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.